AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8205090
Drug: Oral pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentoxifylline (PTX) 400 mg every 4 hours from day -10 until day +35 or discharge
Trial: 3109069
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 25 mg/day
Trial: 3109069
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 125 mg/day
Trial: 3109069
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 250 mg/day
Trial: 3109069
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg/day
Trial: 22440975
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg dexamphetamine
Trial: 23545372
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help treatment of pediatric obesity (GSH-PO)
Trial: 21576556
Drug: Intranasal aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal aqueous triamcinolone acetonide, administered once daily for 6 weeks
Trial: 21576556
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered once daily for 6 weeks
Trial: 21576556
Drug: Intranasal aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal aqueous triamcinolone acetonide
Trial: 15095852
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/day for 8 weeks, 6 mg/day for 4 weeks)
Trial: 15095852
Drug: Prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1 mg/kg/day for 4 weeks, tapering for 8 weeks)
Trial: 23916925
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg twice daily (n = 30)
Trial: 18069016
Drug: Subacromial steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial steroid injections
Trial: 18069016
Drug: Both physiotherapy
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both physiotherapy and steroid injections
Trial: 16794461
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (150 mg of cocoa flavanols for 5 days)
Trial: 16794461
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (450 mg of flavanols - single acute dose)
Trial: 30590423
Drug: Increased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased insulin resistance (measured by HOMA-IR)
Trial: 26849119
Drug: Carbocysteine 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocysteine 1500 mg daily
Trial: 25132282
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (30 mg of lansoprazole, 1g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily for 10 days)
Trial: 25132282
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (30 mg of lansoprazole, 1g of amoxicillin, and 500 mg of clarithromycin, twice daily for 10 days)
Trial: 10933337
Drug: Butorphanol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (3 mg/70 kg)
Trial: 10933337
Drug: Butorphanol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (6 mg/70 kg)
Trial: 10933337
Drug: Morphine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (15 mg/70 kg)
Trial: 10933337
Drug: Morphine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (30 mg/70 kg)
Trial: 10933337
Drug: Lorazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (4 mg/70 kg)
Trial: 8156482
Drug: 5-FU (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (425 mg/m2) and LV (20 mg/m2) for 5 days
Trial: 8156482
Drug: 5-FU (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (425 mg/m2) and LV (20 mg/m2) plus CDDP (20 mg/m2 for 4 consecutive days)
Trial: 3073655
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of CF with constant dose of FUra 400 mg/m2
Trial: 3073655
Drug: Oral CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CF with escalating doses of FUra
Trial: 29602626
Drug: Intra-alveolar administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-alveolar administration of epsilon-aminocaproic acid (EACA) and daily gentle rinsing with EACA mouthwash
Trial: 28133766
Drug: RBP-7000 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP-7000 (90 mg and 120 mg)
Trial: 11115050
Drug: IFN-alpha2b (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 24 weeks
Trial: 11115050
Drug: IFN-alpha2b (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 48 weeks
Trial: 9058441
Drug: Diet providing
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet providing 20 g/d lactose
Trial: 8375836
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment program (18 weeks)
Trial: 8375836
Drug: Control (delayed-treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (delayed-treatment)
Trial: 3890505
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil (16 mg)
Trial: 3890505
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (10 mg)
Trial: 3890505
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (verapamil and metoprolol)
Trial: 3890505
Drug: Metoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (10 mg) during upright bicycle exercise
Trial: 3890505
Drug: Verapamil (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (16 mg) during upright bicycle exercise
Trial: 3890505
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy during upright bicycle exercise
Trial: 30797084
Drug: Dalbavancin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin 1500 mg intravenously as a single dose
Trial: 30797084
Drug: Dalbavancin 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin 1000 mg followed by 500 mg a week later (two doses)
Trial: 27632267
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading with two Straumann implants splinted with a Dolder bar, loaded within 48 hours postoperative.
Trial: 27632267
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading with two Straumann implants, loaded 6 weeks postoperative.
Trial: 1425713
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/12 h)
Trial: 18689384
Drug: High-dose potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose potassium citrate (55.5 mEq/d)
Trial: 18689384
Drug: Low-dose potassium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose potassium citrate (18.5 mEq/d)
Trial: 18689384
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g additional fruit and vegetables/d (equivalent of 18.5 mEq alkali)
Trial: 15932387
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with 100 IR grass pollen extract
Trial: 15932387
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with 300 IR grass pollen extract
Trial: 10350223
Drug: Zafirlukast, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast, a cysteinyl leukotriene receptor antagonist, administered for 14 days
Trial: 8607661
Drug: Verapamil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (10 mg bolus over 2 minutes followed by a 30-minute infusion of 0.375 mg/min and then 0.125 mg/min for 3 days)
Trial: 1836595
Drug: Daily plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily plasma exchanges with fresh frozen plasma (15 ml/kg) in albumin (45 ml/kg)
Trial: 1836595
Drug: Daily transfusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily transfusions of fresh frozen plasma (15 ml/kg)
Trial: 6429905
Drug: Monthly supervision
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly supervision of CBD family planning programs
Trial: 15624267
Drug: CEE 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.3 mg/day plus MPA 1.25 mg/day (Group B)
Trial: 15624267
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/day plus MPA 2.5 mg/day (Group A)
Trial: 2951827
Drug: Ipratropium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium 0.5 mg/fenoterol 1.25 mg
Trial: 2951827
Drug: Ipratropium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium 0.5 mg/fenoterol 2.5 mg
Trial: 2951827
Drug: Ipratropium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium 0.5 mg/fenoterol 5.0 mg
Trial: 2951827
Drug: Salbutamol 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 5.0 mg
Trial: 27023345
Drug: Antenatal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal exercise programme (weekly classes from the 20th week of pregnancy)
Trial: 23062413
Drug: Low preoperative
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low preoperative urine hepcidin concentration (median, 15.3 ng/mL)
Trial: 23062413
Drug: Low preoperative
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low preoperative plasma hepcidin concentration (median, 49.2 ng/mL)
Trial: 14768770
Drug: Glimepiride (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111)
Trial: 14768770
Drug: Acarbose (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108)
Trial: 10720032
Drug: High-dose adrenomedullin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenomedullin (5.8 pmol/kg x min)
Trial: 10720032
Drug: Low-dose adrenomedullin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adrenomedullin (2.9 pmol/kg x min)
Trial: 9022839
Drug: Weight training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight training program (upper and lower body exercises, twice per week for 20 weeks)
Trial: 4079669
Drug: Modified amino
RxNorm normalized name: LYSYL-PEG-LAUROYL-MODIFIED AMINO ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified amino acid solution enriched in branched-chain amino acids (BAA)
Trial: 4079669
Drug: Conventional amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional amino acid solution (Azonutril)
Trial: 26774152
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy combined with intraperitoneal hyperthermic chemoperfusion
Trial: 26774152
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only systemic chemotherapy)
Trial: 24400998
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) - 559.2 mg total catechins, 120.4 mg caffeine
Trial: 22997793
Drug: Ultrastructural acupotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrastructural acupotomy therapy at the counter‐Ashi points, treatment given once a week for 1 month.
Trial: 22997793
Drug: Conventional acupuncture‐moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture‐moxibustion therapy, treatment given once daily for 1 month.
Trial: 15363881
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral self-help treatment
Trial: 15363881
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after treatment termination
Trial: 11288822
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (10-40 mg/day)
Trial: 11288822
Drug: Hydrochlorothiazide alone
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide alone or in combination
Trial: 11288822
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with nitrendipine
Trial: 9625908
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (loading dose of 3.2 mg/kg, followed by 1.6 mg/kg daily for 4 days)
Trial: 9625908
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (loading dose of 20 mg/kg, followed by 10 mg/kg every 8 h for at least 48 h, then oral quinine for a total of 7 days)
Trial: 7955999
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and oral hypoglycaemic agents (Group 2)
Trial: 26706833
Drug: Exemestane +
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane + Metformin
Trial: 26706833
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (Tamoxifen followed by Exemestane)
Trial: 16336883
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% cream on both sides of the face
Trial: 16336883
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% cream on one side of the face
Trial: 16336883
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream on both sides of the face
Trial: 1887750
Drug: Famotidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (0.5 mg.kg-1 per dose, two doses)
Trial: 1887750
Drug: Famotidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (0.5 mg.kg-1 per dose, one dose)
Trial: 1887750
Drug: Famotidine (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (one dose) and Placebo (one dose)
Trial: 1887750
Drug: Famotidine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (any dose)
Trial: 30221589
Drug: Telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered cognitive behavioural therapy (TCBT)
Trial: 30221589
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behavioural therapy (CBT)
Trial: 28941657
Drug: Complex rehabilitation
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex rehabilitation combined with complex decongestive therapy (CRCDT)
Trial: 15107413
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine supplement (0.1 g/kg) given four times daily for the first 14 days
Trial: 11059859
Drug: Prednisolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (50 mg/day)
Trial: 8096956
Drug: Halofantrine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (24 mg/kg)
Trial: 8096956
Drug: Halofantrine (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (72 mg/kg, 8 mg/kg every 8 h for 3 days)
Trial: 8096956
Drug: Halofantrine (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (72 mg/kg)
Trial: 8096956
Drug: High-dose Halofantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Halofantrine (72 mg/kg)
Trial: 4036539
Drug: Atropine 0.03
RxNorm normalized name: atropine 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.03 mg/kg p.o.
Trial: 4036539
Drug: Atropine 0.02
RxNorm normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.02 mg/kg i.m.
Trial: 2833543
Drug: Fluvoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150 mg daily for 6 weeks)
Trial: 2833543
Drug: Maprotiline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (150 mg daily for 6 weeks)
Trial: 25520426
Drug: PrEP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (daily oral combination tenofovir disoproxil fumarate plus emtricitabine)
Trial: 21389754
Drug: STEPPS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEPPS plus adjunctive individual therapy
Trial: 18991076
Drug: CEE/MPA (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (1.25 or 2.5 mg/day)
Trial: 18991076
Drug: Tibolone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (1.25 or 2.5 mg/day)
Trial: 12843685
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (group B)
Trial: 12843685
Drug: Oral diltiazem
RxNorm normalized name: diltiazem Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diltiazem (group A)
Trial: 12843685
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drugs (group C)
Trial: 11938827
Drug: 912 compound
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 912 compound (Chinese herbal preparation)
Trial: 8226711
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate 60 mg twice a day (Group 1)
Trial: 8226711
Drug: Ferric polymaltose
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric polymaltose 100 mg daily (Group 2)
Trial: 8226711
Drug: Ferric polymaltose
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric polymaltose 100 mg twice a day (Group 3)
Trial: 25666686
Drug: Rusovastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rusovastatin 40 mg
Trial: 18359360
Drug: Memantine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (up to 20 mg for 90 days)
Trial: 3530367
Drug: H/DHE (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H/DHE (heparin sodium 5000 units plus dihydroergotamine mesylate 0.5 mg, twice a day)
Trial: 3530367
Drug: LMWH/DHE (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH/DHE (low molecular weight heparin 1500 units plus dihydroergotamine mesylate 0.5 mg, once a day)
Trial: 19294863
Drug: Zhizhuwan (ZZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhizhuwan (ZZ) 90 g per day for 1 month
Trial: 19294863
Drug: Cisapride 30
RxNorm normalized name: cisapride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 30 mg per day for 1 month
Trial: 1930916
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (Catapres‐TTS)
Trial: 19622627
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (1.0 mg/m² . d)
Trial: 15605000
Drug: 15 to
RxNorm normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 to 25 mL injection of 1:10,000 solution of epinephrine
Trial: 15605000
Drug: 35 to
RxNorm normalized name: Hydro 35 Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 to 45 mL injection of 1:10,000 solution of epinephrine